C4 Therapeutics, Inc. (CCCC)
Healthcare
- Fundamental
- 2
- Sentiment
- 2
- Technical
- 2
Do Nothing: hard block - fundamentalScore 2 and qualitativeScore 2 both sit below the required floor of 3 (shadow flag false, so no SHADOW_FST9 paper plan), and the chart independently offers no admissible entry - a pullback limit would be countertrend (price 2.76 < sma50 3.13 with macdLine -0.07 < 0) and a breakout stop has no base, with SMA20 3.09 only ~1.4x ATR overhead.
Company overview
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies that degrade disease-related proteins. Its lead candidate, CFT7455, targets multiple myeloma and non-Hodgkin lymphomas. The company also explores treatments for various cancers and has strategic partnerships with Roche, Biogen, and Calico Life Sciences.
Fundamental
weakC4 Therapeutics is a cash-burning biotech with no approved products and high dilution risk.
C4 Therapeutics is a debt-free but deeply unprofitable clinical-stage biotech: TTM revenue of $32.3M is entirely collaboration income and shrinking (down 14.7% year over year for nine months), TTM net loss is $91.1M against $79.7M of operating cash burn, and the share count has swollen about 35% in nine months with 101.2M warrants struck at $2.22 still outstanding. The mitigants are real — $274.7M of cash and marketable securities, zero debt, no going-concern qualification, a self-stated runway to the end of 2028, an improving 2026 burn rate and a $20M Roche upfront with over $1B of potential milestones — but with clinical data not landing until mid-2027 to 2H 2027, a beta of 3.16, a Piotroski score of 1 and negative discounted-cash-flow outputs, this remains a speculative, high-variance holding rather than a fundamentally attractive one.
Sentiment
weakSentiment is mixed with no strong forward catalysts and high short interest.
Post-Q3 digestion with an empty forward calendar: the 2026-11-05 print read as a wash (EPS ahead of consensus on a narrower loss, revenue light of estimates), the analyst reaction was mixed (Guggenheim held Buy but trimmed its target $7 → $6, other summaries report targets being lifted), and the only other live signals — 38.09% short interest and one-sided 10b5-1 insider selling — are positioning facts rather than drivers. The 30–90-day-to-14-day media delta is a mild but determinate deterioration (+0.167 → −0.025, ~0.19), Reddit is indeterminate on a 403 access block, the Red-Flag Screen is clean with no severe or moderate cap in force, and the neutral-trailing-only floor holds this to an absent-to-weak setup rather than a mixed read.
Technical
weakThe stock is in a downtrend below key moving averages with oversold conditions.
Weak-bearish, bounce-only chart. The 2026-11-13 close of 2.76 sits below all nine moving averages (SMA20 3.09, SMA50 3.13, SMA200 3.25, EMA9 2.96, EMA21 3.04, WMA9 2.93, WMA21 3.06, DEMA14 2.92, TEMA14 2.86) after an 18% slide from 3.37 on 2026-10-30; RSI14 39.13 is falling, MACD -0.07/-0.04/-0.04 has just crossed its histogram back negative, and ADX14 15.66 shows the downtrend is developing but not yet strong. The only constructive feature is a two-session base attempt above the 2026-11-12 low of 2.64 with Williams %R at -86.52 (oversold), i.e. a bounce-only profile — hence technicalScore 2, not a bullish setup. Independent of the chart, fundamentalScore 2 and qualitativeScore 2 both fail the Step-00 override floors of 3, so no long entry is admissible.
You’re looking at 2026-11-14 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

